Wassim Daoud Khatoun

Presenting rising star @RashadNawfal post-doc MD in our group working on novel liquid biopsy methods for non-invasive profiling of cancers! Come on down! #ESMO26 @DanaFarber_GU @DanaFarber Also applying for IM match! Don’t miss on him ! @OncoAlert @SylvanBacaLab #MattFreedman

Proud of our superstar fellow @elioibrahim8 presenting his work on clinical & transcriptomic correlates of primary resistance to nivo/ipi in metastatic RCC at #ESMO26! Important work toward understanding why some patients do not respond to immunotherapy! @myESMO @oncoalert

Our superstar postdoc @marc_eid presenting a novel liquid biospy approach for pancreatic cancer subtyping #MattFreedman @SylvanBacaLab @KarlSemaan Stay tuned for more ! #ESMO26 @myESMO @OncoAlert

Rising physician-scientist star in germline/cancer research @DanaFarber @mustafajsalehmd presents exciting findings at #ESMO26 identifying a germline IL7 variant linked to thyroid and joint immune-related toxicities across cancer types. @myESMO @OncoAlert @DanaFarber_GU @SashaGusevPosts

Heme/onc fellowship applicant @reneesaliby looks at mechanisms of resistance to nivolumab in older adults with mRCC. Individualized targeting of these pathways could help overcome resistance. @YaleIMed @DanaFarber @myESMO #ESMO26 @OncoAlert @DanaFarber_GU

Years of work in the making: superstar @BIDMChealth PGY2 @eddy_saad presents our work on the large R2000 cohort, focusing on rare genomic variants in ccRCC @DanaFarber @BraunMDPhD @VanAllenLab @esmo #ESMO26 @OncoAlert @DanaFarber_GU

Our @DanaFarber own @sands_jacob changing Standard of Care in small cell lung cancer @myESMO #ESMO26 @OncoAlert

Dr @WDKhatoun is a super star post-doc @DanaFarber_GU and every IM program would be lucky to have him ! @gungulati @SylvanBacaLab #FreedmanLab

Very excited to welcome four outstanding new faculty to the Lank Center for Genitourinary Oncology @DanaFarber 1) Dr. Nazli Dizman @NazliDizman 2) Dr. Brian Russell @brian_russell39 3) Dr. Hamid Emamekhoo @HamidEmamekhoo 4) Pr. Neeraj Agarwal @neerajaiims They bring complementary expertise spanning clinical investigation, microbiome science, informatics, quality improvement, education, and GU oncology. Hamid and Neeraj will also take on important broader institutional leadership roles @DanaFarber and @Harvard Cancer Consortium @df_hcc We are fortunate to have them—and the @DanaFarber_GU and our patients are in very good hands. Welcome to @CityOfBoston and @DanaFarber!

JUST IN: @FDA approves RAS inhibitor Daraxonrasib in pancreatic cancer. Our @DanaFarber own Dr Brian Wolpin presented the data @ASCO 2026 annual meeting !

Nineteen years ago, I joined Dana-Farber—with a little more hair and far fewer meetings! I’m deeply grateful to the patients who trusted me and to the colleagues, trainees, and teams who made this journey so meaningful. What a privilege—and what a ride!